MTE #29: Seeing Through the Haze—Mastering Noninvasive Tools for Fibrotic Metabolic Dysfunction–Associated Steatohepatitis (Ticketed)

Accurate identification of fibrotic metabolic dysfunction–associated steatohepatitis (MASH) is critical for risk stratification, treatment selection, and referral. Liver biopsy, however, is neither feasible nor appropriate for most patients. Faculty provide a practical, case-based discussion of noninvasive approaches to detecting fibrotic MASH including serum-based scores, elastography, and emerging biomarkers. Speakers emphasize test selection, interpretation in real-world practice, common pitfalls, and strategies for integrating noninvasive tools into efficient clinical workflows across diverse patient populations.